The clinical implications of the Prostate Cancer Prevention Trial
The Prostate Cancer Prevention Trial has been mentioned before in the Comment Section, but several questions were raised by the publication of the results of the trial. These are addressed here and the trial is described in some detail. This review is a good starting point for people interested in t...
Gespeichert in:
| Veröffentlicht in: | BJU international 2003-11, Vol.92 (7), p.667-671 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 671 |
|---|---|
| container_issue | 7 |
| container_start_page | 667 |
| container_title | BJU international |
| container_volume | 92 |
| creator | Marberger, M. Adolfsson, J. Borkowski, A. Fitzpatrick, J. Kirk, D. Prezioso, D. Rabaça, C. Solsona, E. Teillac, P. |
| description | The Prostate Cancer Prevention Trial has been mentioned before in the Comment Section, but several questions were raised by the publication of the results of the trial. These are addressed here and the trial is described in some detail. This review is a good starting point for people interested in the chemoprevention of prostate cancer to review critically the results of the trial for themselves.
Percutaneous nephrostomy for decompression of an obstructed kidney has become an essential part of urological practice, and nephrostomy tubes are also being used in many other endourological procedures. The authors give their opinion as to what constitutes an ideal nephrostomy tube, and comment on the pros and cons of various different types.
The third mini‐review describes the use of trans‐oceanic telerobotics, and describes the development and current use of their new technology.
Disclosures: This manuscript was an outcome of the European Prostate Cancer Forum, which is supported by an unrestricted educational grant from Merck & Co., Inc. |
| doi_str_mv | 10.1046/j.1464-410X.2003.04486.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_587746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71367012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4336-722f2a24c5599b2da74a3a5979928e7ebf73785d8e8820b214787a3dce3ba8383</originalsourceid><addsrcrecordid>eNqNkDtPwzAQgC0EoqXwF1AW2BL8iu0MDKXiqUowtBKb5aQX4ZImJU5p--9xaGhXpjvffXe2P4QCgiOCubiZR4QLHnKC3yOKMYsw50pEmyPU3zeO_3KciB46c26OsS-I-BT1fCSCc9pHw8kHBFlhS5uZIrCLZeGTxlalC6o8aHzzra5cYxoIRqbMoPZn-IayRYJJbU1xjk5yUzi46OIATR_uJ6OncPz6-DwajsOMMyZCSWlODeVZHCdJSmdGcsNMnMgkoQokpLlkUsUzBUpRnFLCpZKGzTJgqVFMsQEKd3vdGparVC9ruzD1VlfG6q706TPQsZKSC89f7_hlXX2twDV6YV0GRWFKqFZOS8KExIR6UO3AzP_U1ZDvVxOsW916rluTurWqW936V7fe-NHL7o5VuoDZYbDz64GrDjDOC85r79C6AxdThRNFPHe749a2gO2_H6DvXqZtxn4Aiuia2A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71367012</pqid></control><display><type>article</type><title>The clinical implications of the Prostate Cancer Prevention Trial</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Marberger, M. ; Adolfsson, J. ; Borkowski, A. ; Fitzpatrick, J. ; Kirk, D. ; Prezioso, D. ; Rabaça, C. ; Solsona, E. ; Teillac, P.</creator><creatorcontrib>Marberger, M. ; Adolfsson, J. ; Borkowski, A. ; Fitzpatrick, J. ; Kirk, D. ; Prezioso, D. ; Rabaça, C. ; Solsona, E. ; Teillac, P.</creatorcontrib><description>The Prostate Cancer Prevention Trial has been mentioned before in the Comment Section, but several questions were raised by the publication of the results of the trial. These are addressed here and the trial is described in some detail. This review is a good starting point for people interested in the chemoprevention of prostate cancer to review critically the results of the trial for themselves.
Percutaneous nephrostomy for decompression of an obstructed kidney has become an essential part of urological practice, and nephrostomy tubes are also being used in many other endourological procedures. The authors give their opinion as to what constitutes an ideal nephrostomy tube, and comment on the pros and cons of various different types.
The third mini‐review describes the use of trans‐oceanic telerobotics, and describes the development and current use of their new technology.
Disclosures: This manuscript was an outcome of the European Prostate Cancer Forum, which is supported by an unrestricted educational grant from Merck & Co., Inc.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1046/j.1464-410X.2003.04486.x</identifier><identifier>PMID: 14616442</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Biological and medical sciences ; chemoprevention ; Diagnostic Errors ; Double-Blind Method ; Enzyme Inhibitors - therapeutic use ; finasteride ; Finasteride - therapeutic use ; Humans ; Incidence ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; PCPT ; prostate biopsy ; prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - prevention & control ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>BJU international, 2003-11, Vol.92 (7), p.667-671</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4336-722f2a24c5599b2da74a3a5979928e7ebf73785d8e8820b214787a3dce3ba8383</citedby><cites>FETCH-LOGICAL-c4336-722f2a24c5599b2da74a3a5979928e7ebf73785d8e8820b214787a3dce3ba8383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1464-410X.2003.04486.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1464-410X.2003.04486.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15280981$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14616442$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1941534$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Marberger, M.</creatorcontrib><creatorcontrib>Adolfsson, J.</creatorcontrib><creatorcontrib>Borkowski, A.</creatorcontrib><creatorcontrib>Fitzpatrick, J.</creatorcontrib><creatorcontrib>Kirk, D.</creatorcontrib><creatorcontrib>Prezioso, D.</creatorcontrib><creatorcontrib>Rabaça, C.</creatorcontrib><creatorcontrib>Solsona, E.</creatorcontrib><creatorcontrib>Teillac, P.</creatorcontrib><title>The clinical implications of the Prostate Cancer Prevention Trial</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>The Prostate Cancer Prevention Trial has been mentioned before in the Comment Section, but several questions were raised by the publication of the results of the trial. These are addressed here and the trial is described in some detail. This review is a good starting point for people interested in the chemoprevention of prostate cancer to review critically the results of the trial for themselves.
Percutaneous nephrostomy for decompression of an obstructed kidney has become an essential part of urological practice, and nephrostomy tubes are also being used in many other endourological procedures. The authors give their opinion as to what constitutes an ideal nephrostomy tube, and comment on the pros and cons of various different types.
The third mini‐review describes the use of trans‐oceanic telerobotics, and describes the development and current use of their new technology.
Disclosures: This manuscript was an outcome of the European Prostate Cancer Forum, which is supported by an unrestricted educational grant from Merck & Co., Inc.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>chemoprevention</subject><subject>Diagnostic Errors</subject><subject>Double-Blind Method</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>finasteride</subject><subject>Finasteride - therapeutic use</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>PCPT</subject><subject>prostate biopsy</subject><subject>prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - prevention & control</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Treatment Outcome</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkDtPwzAQgC0EoqXwF1AW2BL8iu0MDKXiqUowtBKb5aQX4ZImJU5p--9xaGhXpjvffXe2P4QCgiOCubiZR4QLHnKC3yOKMYsw50pEmyPU3zeO_3KciB46c26OsS-I-BT1fCSCc9pHw8kHBFlhS5uZIrCLZeGTxlalC6o8aHzzra5cYxoIRqbMoPZn-IayRYJJbU1xjk5yUzi46OIATR_uJ6OncPz6-DwajsOMMyZCSWlODeVZHCdJSmdGcsNMnMgkoQokpLlkUsUzBUpRnFLCpZKGzTJgqVFMsQEKd3vdGparVC9ruzD1VlfG6q706TPQsZKSC89f7_hlXX2twDV6YV0GRWFKqFZOS8KExIR6UO3AzP_U1ZDvVxOsW916rluTurWqW936V7fe-NHL7o5VuoDZYbDz64GrDjDOC85r79C6AxdThRNFPHe749a2gO2_H6DvXqZtxn4Aiuia2A</recordid><startdate>200311</startdate><enddate>200311</enddate><creator>Marberger, M.</creator><creator>Adolfsson, J.</creator><creator>Borkowski, A.</creator><creator>Fitzpatrick, J.</creator><creator>Kirk, D.</creator><creator>Prezioso, D.</creator><creator>Rabaça, C.</creator><creator>Solsona, E.</creator><creator>Teillac, P.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>200311</creationdate><title>The clinical implications of the Prostate Cancer Prevention Trial</title><author>Marberger, M. ; Adolfsson, J. ; Borkowski, A. ; Fitzpatrick, J. ; Kirk, D. ; Prezioso, D. ; Rabaça, C. ; Solsona, E. ; Teillac, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4336-722f2a24c5599b2da74a3a5979928e7ebf73785d8e8820b214787a3dce3ba8383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>chemoprevention</topic><topic>Diagnostic Errors</topic><topic>Double-Blind Method</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>finasteride</topic><topic>Finasteride - therapeutic use</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>PCPT</topic><topic>prostate biopsy</topic><topic>prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - prevention & control</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Treatment Outcome</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marberger, M.</creatorcontrib><creatorcontrib>Adolfsson, J.</creatorcontrib><creatorcontrib>Borkowski, A.</creatorcontrib><creatorcontrib>Fitzpatrick, J.</creatorcontrib><creatorcontrib>Kirk, D.</creatorcontrib><creatorcontrib>Prezioso, D.</creatorcontrib><creatorcontrib>Rabaça, C.</creatorcontrib><creatorcontrib>Solsona, E.</creatorcontrib><creatorcontrib>Teillac, P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marberger, M.</au><au>Adolfsson, J.</au><au>Borkowski, A.</au><au>Fitzpatrick, J.</au><au>Kirk, D.</au><au>Prezioso, D.</au><au>Rabaça, C.</au><au>Solsona, E.</au><au>Teillac, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical implications of the Prostate Cancer Prevention Trial</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2003-11</date><risdate>2003</risdate><volume>92</volume><issue>7</issue><spage>667</spage><epage>671</epage><pages>667-671</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>The Prostate Cancer Prevention Trial has been mentioned before in the Comment Section, but several questions were raised by the publication of the results of the trial. These are addressed here and the trial is described in some detail. This review is a good starting point for people interested in the chemoprevention of prostate cancer to review critically the results of the trial for themselves.
Percutaneous nephrostomy for decompression of an obstructed kidney has become an essential part of urological practice, and nephrostomy tubes are also being used in many other endourological procedures. The authors give their opinion as to what constitutes an ideal nephrostomy tube, and comment on the pros and cons of various different types.
The third mini‐review describes the use of trans‐oceanic telerobotics, and describes the development and current use of their new technology.
Disclosures: This manuscript was an outcome of the European Prostate Cancer Forum, which is supported by an unrestricted educational grant from Merck & Co., Inc.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>14616442</pmid><doi>10.1046/j.1464-410X.2003.04486.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2003-11, Vol.92 (7), p.667-671 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_587746 |
| source | MEDLINE; Wiley Online Library |
| subjects | Aged Biological and medical sciences chemoprevention Diagnostic Errors Double-Blind Method Enzyme Inhibitors - therapeutic use finasteride Finasteride - therapeutic use Humans Incidence Male Medical sciences Middle Aged Nephrology. Urinary tract diseases PCPT prostate biopsy prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - prevention & control Randomized Controlled Trials as Topic Treatment Outcome Tumors of the urinary system Urinary tract. Prostate gland |
| title | The clinical implications of the Prostate Cancer Prevention Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T17%3A57%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20implications%20of%20the%20Prostate%20Cancer%20Prevention%20Trial&rft.jtitle=BJU%20international&rft.au=Marberger,%20M.&rft.date=2003-11&rft.volume=92&rft.issue=7&rft.spage=667&rft.epage=671&rft.pages=667-671&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1046/j.1464-410X.2003.04486.x&rft_dat=%3Cproquest_swepu%3E71367012%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71367012&rft_id=info:pmid/14616442&rfr_iscdi=true |